Journal of Applied Biological Chemistry

The Korean Society for Applied Biological Chemistry (한국응용생명화학회)
권호 표지
DOI QR코드

DOI QR Code

Antiplatelet activity of esculetin through the down-regulation of PI3K/MAPK pathway

  • Lee, Dong-Ha (Department of Biomedical Laboratory Science, Namseoul University)
  • Received : 2021.08.05
  • Accepted : 2021.09.02
  • Published : 2021.09.30
Download PDF
⟨ Previous Next ⟩

Abstract

Among the different cardiovascular disorders (CVDs), the activation of platelets is a necessary step. Based on this knowledge, therapeutic treatments for CVDs that target the disruption of platelet activation are proving to be worthwhile. One such substance, a bioactive 6,7-dihydroxy derived from coumarin, is 6,7-Dihydroxy-2H-1-benzopyran-2-one (esculetin). This compound has demonstrated several pharmacological effects on CVDS as well as various other disorders including diabetes, obesity, and renal failure. In various reports, esculetin and its effect has been explored in experimental mouse models, human platelet activation, esculetin-inhibited collagen, and washed human platelets exhibiting aggregation via arachidonic acid. Yet, esculetin affected aggregation with agonists like U46619 or thrombin in no way. This study investigated esculetin and how it affected human platelet aggregation activated through U46619. Ultimately, we confirmed that esculetin had an effect on the aggregation of human platelets when induced from U46619 and clarified the mechanism. Esculetin interacts with the downregulation of both phosphoinositide 3-kinase/Akt and mitogen-activated protein kinases, important phosphoproteins that are involved in activating platelets and their signaling process. The effects of esculetin reduced TXA2 production, phospholipase A2 activation, and platelet secretion of intracellular granules (ATP/serotonin), ultimately causing inhibition of overall platelet aggregation. These results clearly define the effect of esculetin in inhibiting platelet activity and thrombus formation in humans.

Keywords

Acknowledgement

Funding for this paper was provided by Namseoul University

References

  1. 1Jackson SP (2011) Arterial thrombosis?insidious, unpredictable and deadly. Nat Med 17: 1423-1436. doi: 10.1038/nm.2515
  2. Morello F, Perino A, Hirsch E (2009) Phosphoinositide 3-kinase esculetin in the vascular system. Cardiovasc Res 82: 261-271. doi: 10.1093/cvr/cvn325
  3. Jennings LK (2009) Role of platelets in atherothrombosis. Am J Cardiol 103:4A-10A. doi: 10.1016/j.amjcard.2008.11.017
  4. Sabatine MS, Jang IK (2000) The use of glycoprotein IIb/ IIIa inhibitors in patients with coronary artery disease. Am J Med 109: 224-237. doi: 10.1016/s0002-9343(00)00474-5
  5. Cattanco M, Tenconi PM, Lecchi A, Mannucci PM (1991) In vitro effects of picotamide on human platelet aggregation, the release reaction and thromboxane B2 production. Thromb Res 62: 717-724. doi: 10.1016/0049-3848(91)90375-7
  6. Su CY, Shiao MS, Wang CT (1999) Differential effects of ganodermic acid S on the thromboxane A2-signaling pathways in human platelets. Biochem Pharmacol 58: 587-595. doi: 10.1016/s0006-2952(99)00136-7
  7. Adam F, Kauskot A, Nurden P, Sulpice E, Hoylaerts MF, Davis RJ (2010) Platelet JNK1 is involved in secretion and thrombus formation. Blood 115: 4083-4092. doi: 10.1182/blood-2009-07-233932
  8. Bugaud F, Nadal-Wollbold F, Levy-Toledano S, Rosa JP, Bryckaert M (1999) Regulation of c-jun-NH2 terminal kinase and extracellular-signal regulated kinase in human platelets. Blood 94:3800-3805 https://doi.org/10.1182/blood.V94.11.3800
  9. Kramer RM, Roberts EF, Strifler BA, Johnstone EM (1995) Thrombin induces activation of p38 MAP kinase in human platelets. J Biol Chem. 270: 27395-27398. doi: 10.1074/jbc.270.46.27395
  10. Nadal-Wollbold F, Pawlowski M, Levy-Toledano S, Berrou E, Rosa JP, Bryckaert M (2002) Platelet ERK2 activation by thrombin is dependent on calcium and conventional protein kinases C but not Raf-1 or B-Raf. FEBS Lett 531: 475-482. doi: 10.1016/s0014-5793(02)03587-1
  11. Patrono C (1994) Aspirin as an antiplatelet drug. N Engl J Med 330: 1287-1294. doi: 10.1056/NEJM199405053301808
  12. Flevaris P, Li Z, Zhang G, Zheng Y, Liu J, Du X (2009) Two distinct roles of mitogen-activated protein kinases in platelets and a novel Rac1-MAPK-dependent integrin outside-in retractile signaling pathway. Blood 113: 893-901. doi: 10.1182/blood-2008-05-155978
  13. Kramer RM, Roberts EF, Um SL, Borsch-Haubold AG, Watson SP, Fisher MJ (1996) p38 mitogen-activated protein kinase phosphorylates cytosolic phospholipase A2 (cPLA2) in thrombin-stimulated platelets. Evidence that proline-directed phosphorylation is not required for mobilization of arachidonic acid by cPLA2. J Biol Chem 271: 27723-27729. doi: 10.1074/jbc.271.44.27723.
  14. McNicol A, Shibou TS (1998) Translocation and phosphorylation of cytosolic phospholipase A2 in activated platelets. Thromb Res 92: 19-26. doi: 10.1016/s0049-3848(98)00097-8
  15. Chuang WY, Kung PH, Kuo CY, Wu CC (2013) Sulforaphane prevents human platelet aggregation through inhibiting the phosphatidylinositol 3-kinase/Akt pathway. Thromb Haemost 109: 1120-1130. doi: 10.1160/TH12-09-0636
  16. Karthika P, Rajadurai M, Ganapathy P, Kanchana G (2012) Preventive effect of esculetin on lipid peroxides and antioxidants in isoproterenol-induced myocardial infarction in Wistar rats. J Pharm Res 5: 915-918
  17. Liang C, Ju W, Pei S, Tang Y, Xiao Y (2017) Pharmacological activities and synthesis of esculetin and its derivatives: A mini-review. Molecules 22: 387. doi: 10.3390/molecules22030387
  18. Hsia CW, Shyu KG, Jayakumar T, Hsia CH, Velusamy M, Yang CH, Sheu JR (2019) Natural coumarin derivative esculetin regulates platelet activation via modulating NF-κB signaling in cyclic nucleotide-independent manner. Natural Product Communications 14(12): 1934578X19896663. doi: 10.1177/1934578X19896663
  19. Hsia CW, Lin KC, Lee TY, Hsia CH, Chou DS, Jayakumar T, Velusamy M, Chang CC, Sheu JR (2019) Esculetin, a Coumarin Derivative, Prevents Thrombosis: Inhibitory Signaling on PLCγ2-PKC-AKT Activation in Human Platelets. Int J Mol Sci 20(11): 2731. doi: 10.3390/ijms20112731
  20. Chang MC, Wang TM, Yeung SY, Jeng PY, Liao CH, Lin TY, Lin CC, Lin BR, Jeng JH (2011) Antiplatelet effect by p-cresol, a uremic and environmental toxicant, is related to inhibition of reactive oxygen species, ERK/p38 signaling and thromboxane A2 production. Atherosclerosis 219: 559-565. doi: 10.1016/j.atherosclerosis.2011.09.031
  21. F Cipollone F, Patrignani P, Greco A, Panara MR, Padovano R, Cuccurullo F, Patrono C, Rebuzzi AG, Liuzzo G, Quaranta G, Maseri A. (1997) Differential suppression of thromboxane biosynthesis by indobufen and aspirin in patients with unstable angina. Circulation 96: 1109-1116. doi: 10.1161/01.cir.96.4.1109
  22. Patrono C (2001) Aspirin: new cardiovascular uses for an old drug. Am J Med 110: 62S-65S. doi: 10.1016/s0002-9343(00)00645-8
  23. Calderwood DA (2004) Integrin activation. J Cell Sci 117: 657-666. doi: 10.1242/jcs.01014

Cited by

  1. Profiling oxylipins released from human platelets activated through the GPVI collagen receptor vol.158, 2021, https://doi.org/10.1016/j.prostaglandins.2021.106607